Radiotherapy for renal-cell carcinoma.

Area of Science:

• Oncology
• Radiation Oncology
• Immunology

Background:

• Renal-cell carcinoma (RCC) is traditionally considered radioresistant.
• Stereotactic body radiotherapy (SBRT) challenges this notion with high-dose, hypofractionated regimens.
• Emerging evidence suggests RCC may be radiosensitive under specific SBRT conditions.

Purpose of the Study:

• To evaluate the potential of stereotactic body radiotherapy in managing primary and oligometastatic renal-cell carcinoma.
• To explore the biological mechanisms underlying SBRT efficacy in RCC.
• To investigate the potential for abscopal effects and combination therapies.

Main Methods:

• Application of high-dose per fraction stereotactic body radiotherapy for renal-cell carcinoma.
• Investigation of the ceramide pathway's role in SBRT-induced radiosensitivity.
• Exploration of SBRT-induced abscopal effects and immunomodulation.

Main Results:

• High-dose SBRT demonstrates potential efficacy in primary and metastatic RCC.
• Activation of the ceramide pathway by high-dose SBRT provides a biological rationale for radiosensitivity.
• SBRT may induce abscopal effects, potentially augmented by targeted therapies.

Conclusions:

• Renal-cell carcinoma may not be as radioresistant as previously thought, particularly with SBRT.
• Stereotactic body radiotherapy, leveraging the ceramide pathway and abscopal effect, offers a promising treatment strategy.
• Urgent need for prospective, randomized trials combining SBRT with targeted agents.